Current and potential targets for drug design in the androgen receptor pathway for prostate cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current and potential targets for drug design in the androgen receptor pathway for prostate cancer
Authors
Keywords
-
Journal
Expert Opinion on Drug Discovery
Volume 13, Issue 6, Pages 489-496
Publisher
Informa UK Limited
Online
2018-04-06
DOI
10.1080/17460441.2018.1455662
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)
- (2018) Hendrik Borgmann et al. EUROPEAN UROLOGY
- Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests
- (2018) Gonzalo Torga et al. JAMA Oncology
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer
- (2017) Ping Mu et al. SCIENCE
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
- (2017) Sheng Yu Ku et al. SCIENCE
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
- (2017) Jane Goodall et al. Cancer Discovery
- Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer
- (2017) Jennifer Podolak et al. Oncotarget
- HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study
- (2016) Jason W D Hearn et al. LANCET ONCOLOGY
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
- (2016) I. A. Asangani et al. MOLECULAR CANCER RESEARCH
- mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
- (2016) Cara M. Statz et al. Targeted Oncology
- Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
- (2015) S Salvi et al. BRITISH JOURNAL OF CANCER
- Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer
- (2015) Consuelo Buttigliero et al. CANCER TREATMENT REVIEWS
- Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
- (2015) B. Montgomery et al. CLINICAL CANCER RESEARCH
- Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer
- (2015) Benjamin L. Maughan et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis
- (2015) Mark M Pomerantz et al. NATURE GENETICS
- Plasma AR and abiraterone-resistant prostate cancer
- (2015) Alessandro Romanel et al. Science Translational Medicine
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
- (2014) D Lorente et al. BRITISH JOURNAL OF CANCER
- Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2014) C. Liu et al. CLINICAL CANCER RESEARCH
- Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development
- (2014) Michelle A Ojemuyiwa et al. EXPERT OPINION ON EMERGING DRUGS
- Beyond T and DHT - Novel Steroid Derivatives Capable of Wild Type Androgen Receptor Activation
- (2014) Elahe A Mostaghel International Journal of Biological Sciences
- Selectively Targeting the DNA-binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer
- (2014) Kush Dalal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dependence of Castration-Resistant Prostate Cancer (CRPC) Stem Cells on CRPC-Associated Fibroblasts
- (2014) Helty Adisetiyo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- A New Avenue toward Androgen Receptor Pan-antagonists: C2 Sterically Hindered Substitution of Hydroxy-propanamides
- (2014) Andrea Guerrini et al. JOURNAL OF MEDICINAL CHEMISTRY
- Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
- (2014) P. J. Toren et al. MOLECULAR CANCER THERAPEUTICS
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in the treatment of metastatic castration-resistant prostate cancer
- (2014) Elahe Mostaghel Cancer Management and Research
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
- (2013) Andres Jan Schrader et al. EUROPEAN UROLOGY
- An androgen receptor N-terminal domain antagonist for treating prostate cancer
- (2013) Jae-Kyung Myung et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study
- (2013) Elahe A. Mostaghel et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
- (2013) T Karantanos et al. ONCOGENE
- Serum testosterone levels after medical or surgical androgen deprivation: A comprehensive review of the literature
- (2013) Tsutomu Nishiyama UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Peptidomimetic targeting of critical androgen receptor–coregulator interactions in prostate cancer
- (2013) Preethi Ravindranathan et al. Nature Communications
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells
- (2012) B. Sahu et al. CANCER RESEARCH
- Bevacizumab treatment of prostate cancer
- (2012) Alexander C Small et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
- (2012) Himisha Beltran et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen Deprivation Causes Epithelial-Mesenchymal Transition in the Prostate: Implications for Androgen-Deprivation Therapy
- (2011) Y. Sun et al. CANCER RESEARCH
- Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression
- (2011) Y. Li et al. CANCER RESEARCH
- Small Molecule Inhibition of the Steroid Receptor Coactivators, SRC-3 and SRC-1
- (2011) Ying Wang et al. MOLECULAR ENDOCRINOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
- (2011) Emma Hörnberg et al. PLoS One
- Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
- (2011) K.-H. Chang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers
- (2011) Russell Z. Szmulewitz et al. PROSTATE
- 3β-Hydroxysteroid Dehydrogenase Is a Possible Pharmacological Target in the Treatment of Castration-Resistant Prostate Cancer
- (2010) Kristen Evaul et al. ENDOCRINOLOGY
- Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer
- (2010) Lucy J. Schmidt et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
- (2009) K. E. Knudsen et al. CLINICAL CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion
- (2008) Yirong Li et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- TGF-β signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells
- (2007) Meng-Lei Zhu et al. PROSTATE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More